GSK-2269557 manufacturers
|
| | GSK-2269557 Basic information |
| Product Name: | GSK-2269557 | | Synonyms: | GSK-2269557;2-(6-(1H-Indol-4-yl)-1H-indazol-4-yl)-5-((4-isopropylpiperazin-1-yl)methyl)oxazole hydrochloride;GSK2269557 HCL;6-(1H-Indol-4-yl)-4-[5-[[4-(1-methylethyl)-1-piperazinyl]methyl]-2-oxazolyl]-1H-indazole hydrochloride (1:1);GSK-2269557 HCl salt;6-(1H-indol-4-yl)-4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1H-indazole hydrochloride;CS-2463;GSK-2269557 (Nemiralisib HCl) | | CAS: | 1254036-77-5 | | MF: | C26H29ClN6O | | MW: | 477.00106 | | EINECS: | | | Product Categories: | | | Mol File: | 1254036-77-5.mol |  |
| | GSK-2269557 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | ≤0.2mg/ml in ethanol;20mg/ml in DMSO;14mg/ml in dimethyl formamide | | form | crystalline solid |
| | GSK-2269557 Usage And Synthesis |
| Biological Activity | pki : 9.9gsk2269557 is an inhibitor of pi3kδ.phosphoinositide 3-kinase delta (pi3kδ), a lipid kinase belonging to the class 1 pi3k family, catalyzes the phosphorylation of phosphatidylinositol-4,5-bisphosphate to produce the critical signalling molecule phosphatidylinositol-3,4,5-triphosphate and then triggers various downstream biological events that ultimately regulate cell proliferation, growth, differentiation, chemotaxis and survival. | | in vitro | in the screening study, gsk2269557 met the original potency goal in the pbmc assay (pic50 >9) and showed exquisite selectivity against the pi3k isoforms in a modified htrf assay. moreover, gsk2269557 could induce concentration-dependent increases in qt interval and tpe at 0.3 and 1 μm and an increase in qrs at 1 μm, however, no treatment-related tdp arrhythmias were seen [1]. | | in vivo | in a disease relevant brown norway rat acute ova model of th2 driven lung inflammation, gsk2269557 was found to be albe to protect against eosinophil recruitment with an ed50 of 67 μg/kg. the activity of gsk2269557 was also assessed using other endpoints, leukocyte recruitment to the lung (neutrophils, macrophages, cd4 and cd8 t-lymphocytes at 48 hours) and th2 cytokines such as il-13. it was found that gsk2269557 could reduce recruitment of all leukocyte subpopulations and il-13 in the lungs in a dose-dependent manner [1]. | | references | [1] down, k. ,amour, a.,baldwin, i.r., et al. optimization of novel indazoles as highly potent and selective inhibitors of phosphoinositide 3-kinase δ for the treatment of respiratory disease. j. med. chem. 58(18), 7381-7399 (2015).
[2] robert wilson, anthony cahn, amanda deans, iain mcsherry, curtis rambaran, ana sousa, darren wilbraham. safety, tolerability and pharmacokinetics (pk) of single and repeat nebulised doses of a novel phosphoinositide 3-kinase δ inhibitor (pi3kδ), gsk2269557, administered to healthy male subjects in a phase i study. european respiratory journal 2013 42: p729. |
| | GSK-2269557 Preparation Products And Raw materials |
|